28
Participants
Start Date
October 9, 2019
Primary Completion Date
August 5, 2021
Study Completion Date
August 5, 2021
Placebo
Participants will receive injection of placebo matched to SHP655.
SHP655
Participants will receive injection of SHP655.
Standard of Care
Participants will receive PEX as Standard of Care (SOC).
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
Hopital Conception, Marseille
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milan
Hospital General Universitario Gregorio Maranon, Madrid
Medical University of South Carolina (MUSC), Charleston
The University of Alabama at Birmingham, Birmingham
Hospital Universitario Virgen del Rocio, Seville
The Ohio State University Wexner Medical Center, Columbus
Hospital Dr. Peset, Valencia
Hospital Universitari i Politècnic la Fe, Valencia
CHU de Reims - Hôpital Maison Blanche, Reims
University of Minnesota, Minneapolis
Stephenson Cancer Center, Oklahoma City
Chu Saint-Antoine, Paris
CHU de Rouen, Seine Maritime
Brigham and Women's Hospital, Boston
University Hospitals Cleveland Medical Center, Cleveland
London Health Sciences Centre (LHSC) - University Hospital, London
St. Michael's Hospital, Toronto
Hamatologie, Onkologie, Hämostaseologie, Frankfurt
Hospital General Universitario de Alicante, Alicante
University Hospital of Wales, Cardiff
Royal Liverpool University Hospital, Liverpool
1st Floor, UCLH-Haematology, London
Lead Sponsor
Takeda Development Center Americas, Inc.
INDUSTRY
Shire
INDUSTRY